VistaGen Therapeutics (NASDAQ:VTGN) Posts Earnings Results, Beats Estimates By $0.14 EPS

VistaGen Therapeutics (NASDAQ:VTGN) released its quarterly earnings results on Friday. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.14, FiscalAI reports. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%.

VistaGen Therapeutics Stock Up 1.0%

Shares of NASDAQ VTGN traded up $0.00 on Friday, reaching $0.18. 402,286 shares of the company’s stock traded hands, compared to its average volume of 4,567,498. VistaGen Therapeutics has a 12 month low of $0.16 and a 12 month high of $5.14. The business’s 50 day simple moving average is $0.22 and its two-hundred day simple moving average is $0.42. The company has a market cap of $8.01 million, a price-to-earnings ratio of -0.11 and a beta of 0.49.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $0.95.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines. Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder. The company’s pipeline has also included PH80, an intranasal therapy investigated for migraine and other neurological conditions, and PH10, an intranasal neuroactive compound studied for depressive disorders.